Amplia Therapeutics is launching a new clinical trial evaluating its protein inhibitor narmafotinib in ovarian cancer. Multiple Australian outlets report the company is partnering with ANZGOG, a research group, for the study. The trial is positioned as an effort to assess narmafotinib’s potential benefits in people with ovarian cancer, with details such as study design and patient eligibility not specified in the provided reporting. The announcement is covered consistently across sources, with no major differences in the core information. Across the reports, the key elements are that Amplia is initiating the trial, narmafotinib is the investigational drug, and ANZGOG is involved as a partner. The reporting does not describe outcomes, timelines, or regulatory status beyond the fact that the trial is being launched.